A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD

PLoS ONE - Tập 10 Số 6 - Trang e0129865
Qing Zhang1, Yang Zhang1,2, Ke Li1, Li Wang1, Huizhong Li1, Junnian Zheng1,3
1Cancer Institute, Xuzhou Medical College, Xuzhou, Jiangsu, 221002, China
2Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical College, Affiliated Hospital of Southeast University, Xuzhou, Jiangsu, 221009, China
3Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou, Jiangsu 221002, China

Tóm tắt

Từ khóa


Tài liệu tham khảo

R Siegel, 2014, Cancer statistics, 2014, CA: a cancer journal for clinicians, 64, 9

H Ren, 2009, Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer, Molecular cancer therapeutics, 8, 1106, 10.1158/1535-7163.MCT-08-0779

IY Kim, 2009, Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. Journal of controlled release: official journal of the, Controlled Release Society, 140, 55, 10.1016/j.jconrel.2009.07.005

H Wang, 2006, Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9, Molecular cancer therapeutics, 5, 1585, 10.1158/1535-7163.MCT-06-0094

D Ferrigno, 2000, Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?, Lung cancer, 29, 91, 10.1016/S0169-5002(00)00112-4

P Yang, 2005, Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003, Chest, 128, 452, 10.1378/chest.128.1.452

MM Mortenson, 2004, Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line, Cancer chemotherapy and pharmacology, 54, 343, 10.1007/s00280-004-0811-4

SG Spiro, 2002, Lung cancer—where are we today? Current advances in staging and nonsurgical treatment, American journal of respiratory and critical care medicine, 166, 1166, 10.1164/rccm.200202-070SO

H Cortes-Funes, 2002, New treatment approaches for lung cancer and impact on survival, Seminars in oncology, 29, 26, 10.1016/S0093-7754(02)70171-1

B Higgins, 2004, Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models, Anti-cancer drugs, 15, 503, 10.1097/01.cad.0000127664.66472.60

K Cao, 2012, Noxa enhances the cytotoxic effect of gemcitabine in human ovarian cancer cells, Cancer biotherapy & radiopharmaceuticals, 27, 259, 10.1089/cbr.2011.1126

NM Cerqueira, 2007, Understanding ribonucleotide reductase inactivation by gemcitabine, Chemistry, 13, 8507, 10.1002/chem.200700260

MD Shelley, 2011, Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma, BJU international, 108, 168, 10.1111/j.1464-410X.2011.10341.x

MK Kim, 2011, The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-kappaB activity and down-regulating Bfl-1, Molecular cancer, 10, 98, 10.1186/1476-4598-10-98

G Marx, 2002, Non-platinum gemcitabine combinations in non-small cell lung cancer, Lung cancer, 38, S51, 10.1016/S0169-5002(02)00358-6

L Kraus-Berthier, 2000, Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clinical cancer research: an official journal of the, American Association for Cancer Research, 6, 297

J Dancey, 1997, Non-small cell lung cancer: an overview of current management, European journal of cancer, 33, S2, 10.1016/S0959-8049(96)00325-5

KN Sugahara, 2009, Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors, Cancer Cell, 16, 510, 10.1016/j.ccr.2009.10.013

CH Heldin, 2004, High interstitial fluid pressure—an obstacle in cancer therapy, Nat Rev Cancer, 4, 806, 10.1038/nrc1456

AJ Primeau, 2005, The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors, Clinical cancer research: an official journal of the American Association for Cancer Research, 11, 8782, 10.1158/1078-0432.CCR-05-1664

JH Baker, 2008, Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clinical cancer research: an official journal of the, American Association for Cancer Research, 14, 2171

KN Sugahara, 2009, Tissue-penetrating delivery of compounds and nanoparticles into tumors, Cancer cell, 16, 510, 10.1016/j.ccr.2009.10.013

S Su, 2013, iRGD-coupled responsive fluorescent nanogel for targeted drug delivery, 34, 3523

KN Sugahara, 2010, Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs, Science, 328, 1031, 10.1126/science.1183057

Q Zhang, 2012, Factor VII light chain-targeted lidamycin shows intensified therapeutic efficacy for liver cancer, Cancer biotherapy & radiopharmaceuticals, 27, 384, 10.1089/cbr.2012.1209

K Aizawa, 2013, Development of ferret as a human lung cancer model by injecting 4-(Nmethyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), Lung cancer, 82, 390, 10.1016/j.lungcan.2013.09.012

C Pellet-Many, 2008, Neuropilins: structure, function and role in disease, The Biochemical journal, 411, 211, 10.1042/BJ20071639

L Roth, 2012, Transtumoral targeting enabled by a novel neuropilin-binding peptide, Oncogene, 31, 3754, 10.1038/onc.2011.537

LR Wang, 2005, Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer, Journal of Zhejiang University Science B, 6, 446, 10.1631/jzus.2005.B0446

B Pauwels, 2005, Combined modality therapy of gemcitabine and radiation, The oncologist, 10, 34, 10.1634/theoncologist.10-1-34

R Takebayashi, 2013, [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer, J Exp Clin Cancer Res, 32, 34, 10.1186/1756-9966-32-34

T Teesalu, 2009, C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration, Proc Natl Acad Sci U S A, 106, 16157, 10.1073/pnas.0908201106

W Dai, 2015, A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma, Drug Deliv, 22, 10, 10.3109/10717544.2014.903580

K Wang, 2014, Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates, Biomaterials, 35, 8735, 10.1016/j.biomaterials.2014.06.042

Zhang X, Yu, Zhang W-Q, Luo L-M, Song, Li D, et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. International Journal of Nanomedicine. 2013:2473. <comment>doi: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/ijn.s46962" xlink:type="simple">10.2147/ijn.s46962</ext-link></comment>

J Shen, 2014, iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance, Mol Pharm, 11, 2579, 10.1021/mp400576f

R Du, 2014, Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma, Int J Nanomedicine, 9, 3091

Z Hai-Tao, 2011, A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo, Anticancer Drugs, 22, 409, 10.1097/CAD.0b013e328342050d

G Gu, 2013, The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells, Biomaterials, 34, 5138, 10.1016/j.biomaterials.2013.03.036

W Song, 2012, Methoxypoly(ethylene glycol)-block-Poly(L-glutamic acid)-Loaded Cisplatin and a Combination With iRGD for the Treatment of Non-Small-Cell Lung Cancers, Macromol Biosci, 12, 1514, 10.1002/mabi.201200145

Y Akashi, 2014, Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1, Br J Cancer, 110, 1481, 10.1038/bjc.2014.49

Y Zhang, 2013, Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC, Mol Ther, 21, 1559, 10.1038/mt.2013.120

C Gridelli, 2003, Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial, J Natl Cancer Inst, 95, 362, 10.1093/jnci/95.5.362

C Gridelli, 2008, The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients, Lung Cancer, 61, 67, 10.1016/j.lungcan.2007.12.002

V Bianco, 2002, Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase II study, Anticancer Res, 22, 3053

E Quoix, 2005, First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule, Lung Cancer, 47, 405, 10.1016/j.lungcan.2004.08.012

G Altavilla, 2000, Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer, Anticancer Res, 20, 3675

S Ricci, 2000, Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study, Lung Cancer, 27, 75, 10.1016/S0169-5002(99)00098-7

AJ Sanchez, 2006, Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein, Journal of virology, 80, 514, 10.1128/JVI.80.1.514-525.2006

RJ Wool-Lewis, 1999, Endoproteolytic processing of the ebola virus envelope glycoprotein: cleavage is not required for function, Journal of virology, 73, 1419, 10.1128/JVI.73.2.1419-1426.1999